Partnership aims to leverage cutting-edge technology in clinical trials
Category: News
Breast cancer therapy offers hope for patients at risk of recurrence
Partnership aims to create recombinant nanobodies to treat immune disorders
Study shows AP-325 offers lasting pain relief without central side effects
Funding led by new investors FSG and EIC Fund
Positive opinion issued for marketing authorisation extension
Phase 3 trial of Descartes-08 in myasthenia gravis to start in 1H25
Patients and care partners may find once every four weeks maintenance dosing easier
Study highlights VE303’s potential in reducing recurrent CDI